Market News

Clover Partners LP Has Raised Its Bcb Bancorp (BCBP) Holding; Deciphera Pharmaceuticals (DCPH) Shorts Lowered By 91.26%

Clover Partners Lp increased Bcb Bancorp Inc (BCBP) stake by 177.46% reported in 2017Q2 SEC filing. Clover Partners Lp acquired 66,549 shares as Bcb Bancorp Inc (BCBP)’s stock rose 7.88%. The Clover Partners Lp holds 104,049 shares with $1.59M value, up from 37,500 last quarter. Bcb Bancorp Inc now has $218.71 million valuation. The stock decreased 0.34% or $0.05 during the last trading session, reaching $14.55. About 61,676 shares traded. BCB Bancorp, Inc. (NASDAQ:BCBP) has risen 53.81% since December 2, 2016 and is uptrending. It has outperformed by 37.11% the S&P500.

Deciphera Pharmaceuticals Incorporated (NASDAQ:DCPH) had a decrease of 91.26% in short interest. DCPH’s SI was 41,800 shares in December as released by FINRA. Its down 91.26% from 478,400 shares previously. With 193,200 avg volume, 0 days are for Deciphera Pharmaceuticals Incorporated (NASDAQ:DCPH)’s short sellers to cover DCPH’s short positions. The stock decreased 1.56% or $0.31 during the last trading session, reaching $19.55. About 70,966 shares traded. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 0.00% since December 2, 2016 and is . It has underperformed by 16.70% the S&P500.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company has market cap of $637.17 million. The firm develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It currently has negative earnings. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors.

Among 3 analysts covering BCB Bancorp (NASDAQ:BCBP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BCB Bancorp had 3 analyst reports since September 14, 2017 according to SRatingsIntel. The company was initiated on Thursday, September 14 by Keefe Bruyette & Woods.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *